Undisclosed Bispecific ADC Pipeline
Solid Tumor Cancers
Pre-clinicalActive
Key Facts
About NEOK Bio
NEOK Bio is a private, pre-clinical stage biotech pioneering next-generation bispecific antibody drug conjugates (ADCs) for oncology. The company leverages a proprietary platform and the antibody engineering capabilities of its strategic backer, ABL Bio, to develop dual-targeting ADCs designed for enhanced tumor selectivity and reduced toxicity. With a seasoned leadership team and a pipeline focused on validated targets, NEOK aims to address significant unmet needs in solid tumor cancers.
View full company profileTherapeutic Areas
Other Solid Tumor Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| TP-317 | Thetis Pharmaceuticals | Preclinical/Undisclosed |
| CancerVision | Inocras | Commercial |
| Mini-CAR for Solid Tumors | Caravan Biologix | Pre-clinical |